TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: an echocardiographic measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: reporting of all adverse events [AEs] (serious and non-serious)
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical Opiate Withdrawal Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary latency 12-months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Total WOMAC Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: COPD exacerbation prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Hemoglobin Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of biomarkers of cartilage metabolism and inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Improvement of encephalopathy by one or more grades
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Knee function assessment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to detection of atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Identification of COPD exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: HDRS-24 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic outcome of the PET/CT study
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MMR rates at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical response and clinical remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver histology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wound surface area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: preoperative detection of colorectal liver metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time-to-first event of CV death or HF hospitalisation
Endpoint domain: Mortality/survival
Primary endpoint: Rate of total (first and recurrent) events of hospitalisations for heart failure (HF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pure Tone Averages
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Tumor Markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Nonfatal Myocardial Reinfarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Adverse events reported by prostate patients
Endpoint domain: Adverse events/effects
Primary endpoint: Mean difference in spinal pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parent-reported Tooth Brushing Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child Dental Plaque Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in AISRS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in marginal adaptation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in discoloration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in surface of the restoration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Index of curvature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Intraocular Pressure (IOP) ≥ 5mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circumferential PEDSR rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional connectivity of rs-fMRI Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: change in the intensity of skin disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Improvement in symptoms
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Overall impairment
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Time to requirement of additional systemic pain medication for oesophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Numbers of circulating tumor cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Composite Major Adverse Event (MAE) Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Intraprocedural Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Clinical Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical evolution of Covid19 infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical proprioception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: PaO2/FiO2 ratio changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sustained Virologic Response 12 Weeks Post-treatment (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Anti Influenza Type A/H1N1 Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titer (GMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti Influenza Type A/H2N3 Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titer (GMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti Influenza Type B Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titer (GMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti Influenza Type A/H1N1 Seroconversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Feasibility of whole-exome sequencing and genetic/genomic methods
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Accuracy of FLT PET in classifying tumors as benign or malignant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of FLT PET in patients with NF1 and concerning lesions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of patients free of breast cancer
Endpoint domain: Mortality/survival
Primary endpoint: Patient perceptions of shared decision-making
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in Trough FEV1 (L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Body Fat Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall success at 24 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fusion success at 24 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Daytime symptoms of sleep related worry
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Daytime symptoms
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in Communication Assessment Tool (CAT) scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Pathological state of the tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of tumor infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Presence of IDH mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Suicide repetition
Endpoint domain: Mortality/survival
Primary endpoint: Death by suicide
Endpoint domain: Mortality/survival
Primary endpoint: JOA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cobb angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change from baseline in SF36 Quality of Life Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pain in active motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in forced expiratory volume in 1 second (FEV1) (%predicted)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in peak oxygen uptake (% predicted)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in number of steps per day
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Facial Wrinkle Scale (FWS) score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in six-minutes walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Higher scoring in Kansas City Cardiomyopathy Questionnaire (KCCQ)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of Major Adverse Cardiac Events (MACE)
Endpoint domain: Adverse events/effects
Primary endpoint: Target Vessel Failure (TVF) rate
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of Dementia-related Behavioral Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Caregiver Distress/Strain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Intrinsic Motivation Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ApoB Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Change From Pre-PRP Best Corrected Visual Acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Change in Hemoglobin Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maximum tolerated dose (MTD) of TQ-B3395
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose-limiting toxicity(ies) (DLT[s]) of TQ-B3395
Endpoint domain: Adverse events/effects
Primary endpoint: Peak Plasma Concentration (Cmax) of TQ-B3395
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume excess variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Adverse Event Leading to TAK-079 Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Completed mobile data and questionnaires
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Sudden Cardiac Death
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of arachidonic acid inhibition of platelets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: diagnosis of HES
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Number of Hours of Required Phototherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stigmatising attitude
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: QT interval corrected according to Fridericia (QTcF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in LUTS, anorectal and sexual complaints
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adenoviral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preterm delivery before 37 weeks gestation
Endpoint domain: Mortality/survival
Primary endpoint: Cerebral performance category
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Trabecular volumetric bone mineral density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Participants Who Experienced a Treatment Emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Skin changes or redness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Preoperative level of human epididymis protein 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgicopathological staging of endometrial carcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in volume of Oxygen Consumed at Maximal Exertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phosphorylation of myosin binding protein c (MyBP-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of anxiety levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Composite incidence of NEC, LOS, or death
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Patients With Modified Rankin Scale (mRS 0-1) (Favourable Outcome) Response at Day 90
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Patients With Symptomatic Intracranial Haemorrhage (sICH)
Endpoint domain: Adverse events/effects
Primary endpoint: Time From Induction of Labor to Delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: number of patients who are tobacco abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Melanoma-specific survival
Endpoint domain: Mortality/survival
Primary endpoint: Microchimerism levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in ESSDAI Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety of the technique
Endpoint domain: Adverse events/effects
Primary endpoint: Mean adipocyte size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Appropriate aspirin use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Sensitivity of 11C Acetate PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Substrate oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Liver function worsening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Assisting Hand Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of structural birth defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of chromosomal birth defects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Adverse Pregnancy Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Number of Participants With Emesis
Endpoint domain: Adverse events/effects
Primary endpoint: Neuropsychological measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: skin lesion responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Participants With FMT Failure
Endpoint domain: Adverse events/effects
Primary endpoint: Cognitive scores of children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor scores of children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Socioemotional scores of children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Longitudinal Strain Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of serum Luteinizing Hormone (LH) value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change of serum Follicle-Stimulating Hormone (FSH) value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change of serum total testosterone value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of participants with correct Inhaler technique
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients downstaged according to T stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-free survival at 12 months
Endpoint domain: Mortality/survival
Primary endpoint: Haemoglobin concentration (Hb) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maximal functional capacity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Symptom improvement in gastroesophageal reflux disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of patients with surgical site infection
Endpoint domain: Adverse events/effects
Primary endpoint: Activity-specific balance confidence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maximal post prandial blood glucose concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to maximal post prandial glucose concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 24h total morphine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of DLTs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Drug-related TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Treatment-emergent Serious AE
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Displaying Unsafe Swallowing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Displaying Post-swallow Inhalation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of the Respiratory Pause Seen in Swallowing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ankle Brachial Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cronbach's Alpha coefficient
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: DASH questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Pharmacokinetic profile of nicotine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability assessment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Presence of severe post-thrombotic syndrome at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Rate of relapse after 5 years of treatment
Endpoint domain: Mortality/survival
Primary endpoint: Functional Capacity (6-minute walk test)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum total skin dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Self reports of anal sex with and without condoms
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in Apnea Hypopnea Index (AHI4%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Oxyhemoglobin Desaturation Index (ODI4%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of Dose limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Myasthenia Gravis-Activities of Daily Living (MG-ADL)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change from baseline in breathlessness when walking/climbing stairs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in overall severity of the clinical picture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transporter-Mediated Interaction (TMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early incidence of OA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Distant metastasis free survival
Endpoint domain: Mortality/survival
Primary endpoint: Change in momentary levels of self-reported distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: EGG compatibility with age
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Postoperative
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tumor-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Vital signs data assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart rate assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Respiratory signs data assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes